Insurance companies are pulling the plug on coverage for GLP-1 weight loss medications, citing skyrocketing costs that could increase premiums by nearly 30% for employees. The University of Missouri became the latest major employer to drop coverage for drugs like Wegovy (semaglutide) and Zepbound (tirzepatide) when used for weight management, a trend that mirrors decisions by other large health systems across the country. Beginning January 1, 2026, the University of Missouri stopped covering GLP-1 medications prescribed for weight loss, though the plan continues to cover these drugs when prescribed for Type 2 diabetes treatment. The university cited rising insurance premiums as the reason for the change. "As a self-insured organization, the university pays for all health care and prescription costs for plan members. Continuing coverage for GLP-1 medications, outside of diabetes treatment, would have resulted in a 28% increase in insurance premiums for all employees," according to a university spokesperson. Why Are Insurers Cutting Coverage Despite Growing Demand? The decision reflects a broader cost crisis in the insurance industry. According to research from JPMorganChase, 9.8 million Americans were taking GLP-1 medications in 2025, up from 6.8 million in 2024 and 5.2 million in 2023. The firm estimates that as many as 25 million Americans could be using these drugs by 2030 as demand continues to grow. This explosive growth has strained insurance budgets, forcing companies to make difficult coverage decisions. The impact on patients is significant. According to GoodRx research, the number of people without commercial insurance coverage for Wegovy increased by 42% in 2026 compared with the year before, leaving more than 41 million people without coverage. For Zepbound, the number of people without coverage rose 12%, leaving more than 109 million people without coverage. What Health Benefits Are Patients Losing Access To? Healthcare providers argue that cutting coverage ignores substantial health improvements beyond weight loss. Tricia Temmen, a nurse practitioner at SSM Health Medical Group, emphasized the broader medical value of these medications. "I feel like it helps with body image and, therefore, depression. We know the cardiovascular benefits of weight loss," Temmen stated. "In the Midwest, generally speaking, we have a lot of people who fall into an obese category, mildly obese. Probably the biggest thing that I have seen more and more of over the last several years is fatty liver disease, and that is what I prescribe GLPs for more than any other reason". "I feel like it helps with body image and, therefore, depression. We know the cardiovascular benefits of weight loss. Probably the biggest thing that I have seen more and more of over the last several years is fatty liver disease, and that is what I prescribe GLPs for more than any other reason," explained Tricia Temmen. Tricia Temmen, Nurse Practitioner at SSM Health Medical Group Fatty liver disease, which occurs when excess fat builds up in the liver, is increasingly recognized as a leading cause of cirrhosis as long-term inflammation and damage can gradually scar the organ. Approximately 35% of adults in Missouri have obesity, according to a 2025 report from the American Diabetes Association, making access to effective treatments particularly important in the region. How Are Drug Prices Affecting Insurance Decisions? The Trump administration has attempted to address drug pricing through a Most Favored Nation approach, tying U.S. prices to the lowest prices charged in other wealthy countries. In May 2025, Trump signed an executive order directing federal agencies to pursue policies aimed at bringing U.S. drug prices closer to those lower international prices. Drugmakers were encouraged to adopt the discounts voluntarily after the administration warned it could pursue regulatory actions if companies did not begin aligning U.S. prices with those in other developed countries. So far, the Trump administration has reached voluntary drug price agreements with 16 pharmaceutical companies, though many details remain unclear due to confidentiality. In February, the administration launched TrumpRx.gov, a site that does not sell medications directly but instead redirects users to drugmakers' purchasing programs or coupons, which can lower prices for people paying cash. However, because most Americans get their prescription drugs through private insurance plans or Medicare, the discounts have not yet reached the majority of patients. This gap between available discounts and actual patient access highlights the ongoing tension between drug manufacturers, insurers, and patients seeking affordable treatment options. Steps to Navigate GLP-1 Coverage Changes - Check Your Plan: Contact your employer's human resources department or your insurance provider directly to confirm whether GLP-1 medications for weight loss are covered under your specific plan, as coverage policies vary significantly by employer and insurer. - Explore Manufacturer Programs: Visit drugmakers' websites or TrumpRx.gov to find purchasing programs, coupons, and discount options that may reduce out-of-pocket costs if your insurance no longer covers these medications. - Discuss Diabetes Coverage: If you have Type 2 diabetes, confirm that your plan continues to cover GLP-1 medications for diabetes management, as most insurers maintain this coverage even when dropping weight loss indications. - Talk to Your Doctor: Work with your healthcare provider to explore alternative weight management strategies, including other approved medications, lifestyle modifications, or bariatric surgery options if GLP-1 drugs are no longer accessible through your insurance. The insurance coverage crisis reflects a fundamental challenge in modern healthcare: balancing the high cost of innovative medications with patient access and health outcomes. While GLP-1 drugs have demonstrated significant benefits for weight loss, cardiovascular health, and metabolic conditions like fatty liver disease, their expense has forced insurers to make difficult decisions about which patients can access them. As demand continues to surge and more Americans seek these treatments, the gap between those who can afford them and those who cannot continues to widen, raising questions about equity in healthcare access.
